HanAll Biopharma

Interon Laboratories is developing a new category of immunotherapy for neuro-immunotherapy.

Turn.bio is a biotechnology company developing drugs to reverse aging and age-related diseases. Utilizing its patented mRNA platform technology ERA, the company targets indications in immune-related diseases like cancer and dermatological conditions, as well as therapies for ophthalmology, osteoarthritis, and the muscular system.

Alloplex Biotherapeutics, Inc. is a biotechnology company based in Woburn, Massachusetts, focused on developing innovative anti-tumor vaccines. Founded in 2016, the company has created a non-engineered, tumor-agnostic cellular therapy platform designed to engage critical components of the immune system, such as dendritic cells and lymphocytes. This platform utilizes a tumor-type specific cell line combined with proprietary immunomodulatory gene cassettes to enhance immune responses against various cancers, offering a promising approach for effective cancer treatment. Alloplex Biotherapeutics aims to improve the efficacy of cancer therapies through its unique cellular therapeutics, positioning itself as a significant player in the biotherapeutics landscape.

NurrOn Pharmaceuticals is an innovative pharmaceutical company focused on developing disease-modifying therapies for Parkinson's disease and other Nurr1-related disorders. The company is dedicated to creating novel targeted therapeutics aimed at alleviating symptoms of these conditions by protecting dopaminergic neurons, which are crucial for motor control and function. Through its research and development efforts, NurrOn Pharmaceuticals seeks to improve clinical outcomes for patients suffering from Parkinson's disease, addressing a significant unmet medical need in the treatment of this incurable disorder.